Patients with cancer and atrial fibrillation treated with doacs: A prospective cohort study

•The study includes 2288 prospectively followed patients with non-valvular AF receiving DOACs.•Major bleeding and thromboembolic events are two fold higher in cancer compared to non cancer AF patients receiving DOACs.•The HR was 2.02 (95% CI 1.25–3.27) for major bleedings and 2.58 (95% CI 1.08–6.16) for thromboembolic events.•In cancer patients an excess of bleeding at gastrointestinal and at genitourinary sites was found.•Further evidence is needed on the optimal anticoagulant strategies of AF patients with cancer.